文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

IgA 在针对 SARS-CoV-2 的早期中和抗体反应中占主导地位。

IgA dominates the early neutralizing antibody response to SARS-CoV-2.

机构信息

Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 boulevard de l'Hôpital, 75013 Paris, France.

Département d'Immunologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, 83 boulevard de l'Hôpital, 75013 Paris, France.

出版信息

Sci Transl Med. 2021 Jan 20;13(577). doi: 10.1126/scitranslmed.abd2223. Epub 2020 Dec 7.


DOI:10.1126/scitranslmed.abd2223
PMID:33288662
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7857408/
Abstract

Humoral immune responses are typically characterized by primary IgM antibody responses followed by secondary antibody responses associated with immune memory and composed of IgG, IgA, and IgE. Here, we measured acute humoral responses to SARS-CoV-2, including the frequency of antibody-secreting cells and the presence of SARS-CoV-2-specific neutralizing antibodies in the serum, saliva, and bronchoalveolar fluid of 159 patients with COVID-19. Early SARS-CoV-2-specific humoral responses were dominated by IgA antibodies. Peripheral expansion of IgA plasmablasts with mucosal homing potential was detected shortly after the onset of symptoms and peaked during the third week of the disease. The virus-specific antibody responses included IgG, IgM, and IgA, but IgA contributed to virus neutralization to a greater extent compared with IgG. Specific IgA serum concentrations decreased notably 1 month after the onset of symptoms, but neutralizing IgA remained detectable in saliva for a longer time (days 49 to 73 post-symptoms). These results represent a critical observation given the emerging information as to the types of antibodies associated with optimal protection against reinfection and whether vaccine regimens should consider targeting a potent but potentially short-lived IgA response.

摘要

体液免疫反应的特征通常是初次 IgM 抗体反应,随后是与免疫记忆相关的二次抗体反应,包括 IgG、IgA 和 IgE。在这里,我们测量了 159 名 COVID-19 患者的 SARS-CoV-2 急性体液免疫反应,包括血清、唾液和肺泡灌洗液中抗体分泌细胞的频率和 SARS-CoV-2 特异性中和抗体的存在。早期 SARS-CoV-2 特异性体液免疫反应以 IgA 抗体为主。在症状出现后不久,就检测到具有黏膜归巢潜力的 IgA 浆母细胞的外周扩张,并在疾病的第三周达到高峰。病毒特异性抗体反应包括 IgG、IgM 和 IgA,但与 IgG 相比,IgA 对病毒中和的贡献更大。症状出现后 1 个月,特异性 IgA 血清浓度明显下降,但中和性 IgA 在唾液中可检测到更长时间(症状后第 49 至 73 天)。鉴于有关与再感染最佳保护相关的抗体类型的信息不断涌现,以及疫苗方案是否应考虑针对有效但可能短暂的 IgA 反应,这些结果是一项重要观察。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de04/7857408/5ade71ab5ac5/abd2223-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de04/7857408/d8fee02a04bb/abd2223-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de04/7857408/a71e1e36a51e/abd2223-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de04/7857408/5ade71ab5ac5/abd2223-F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de04/7857408/d8fee02a04bb/abd2223-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de04/7857408/a71e1e36a51e/abd2223-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de04/7857408/5ade71ab5ac5/abd2223-F3.jpg

相似文献

[1]
IgA dominates the early neutralizing antibody response to SARS-CoV-2.

Sci Transl Med. 2021-1-20

[2]
Enhanced SARS-CoV-2 neutralization by dimeric IgA.

Sci Transl Med. 2021-1-20

[3]
Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.

J Immunol Methods. 2021-2

[4]
Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.

Transfusion. 2020-9-16

[5]
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.

J Allergy Clin Immunol. 2021-2

[6]
Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection.

Front Immunol. 2021

[7]
SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.

J Med Virol. 2021-9

[8]
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.

Front Immunol. 2021

[9]
A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.

Infection. 2021-2

[10]
A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.

J Infect Dis. 2021-7-15

引用本文的文献

[1]
Long-Term Durability and Variant-Specific Modulation of SARS-CoV-2 Humoral and Cellular Immunity over Two Years.

Int J Mol Sci. 2025-8-21

[2]
Modeling Antibody Kinetics Post-mRNA Booster Vaccination and Protection Durations Against SARS-CoV-2 Infection.

J Med Virol. 2025-8

[3]
Mucosal Vaccination Against SARS-CoV-2 Using Human Probiotic Spores as an Adjuvant Induces Potent Systemic and Mucosal Immunity.

Vaccines (Basel). 2025-7-21

[4]
Loss of IgA and IgM Compromises Broad Neutralization of Structurally Divergent SARS-CoV-2 Variants.

Antibodies (Basel). 2025-7-12

[5]
The quantity and quality of B-cell immunity against SARS-CoV-2 in children with cancer and hematological diseases.

Front Immunol. 2025-7-2

[6]
A Modular Bacteriophage T4 Nanoparticle Platform Enables Rapid Design of Dual COVID-19-Flu Mucosal Vaccines.

Small Sci. 2025-1-28

[7]
Intranasal booster induces durable mucosal immunity against SARS-CoV-2 in mice.

Sci Rep. 2025-7-7

[8]
Human saliva exerts strong type-dependent effects on adenovirus infectivity.

Front Immunol. 2025-6-11

[9]
Self-assembling TLR2 agonists promote mucosal immune responses without pulmonary immunopathologic injuries in mice.

NPJ Vaccines. 2025-6-18

[10]
Deconvolution of cargo delivery and immunogenicity following intranasal delivery of mRNA lipid nanoparticle vaccines.

Mol Ther Nucleic Acids. 2025-4-24

本文引用的文献

[1]
Enhanced SARS-CoV-2 neutralization by dimeric IgA.

Sci Transl Med. 2021-1-20

[2]
SARS-CoV-2 Receptors and Entry Genes Are Expressed in the Human Olfactory Neuroepithelium and Brain.

iScience. 2020-12-18

[3]
Syncytia formation by SARS-CoV-2-infected cells.

EMBO J. 2020-11-4

[4]
Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia.

Sci Adv. 2020-7-24

[5]
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.

Nat Commun. 2020-8-21

[6]
A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations.

Sci Transl Med. 2020-8-17

[7]
Broad neutralization of SARS-related viruses by human monoclonal antibodies.

Science. 2020-6-15

[8]
Human neutralizing antibodies elicited by SARS-CoV-2 infection.

Nature. 2020-5-26

[9]
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.

Nature. 2020-5-26

[10]
Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients.

Eur Respir J. 2020-8-27

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索